Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 18, 1988 - Issue 6
23
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Metabolism and cytotoxicity of benzo(a)pyrene in the human lung tumour cell line NCI-H322

, &
Pages 747-755 | Published online: 30 Sep 2009
 

Abstract

1. The human lung tumour cells NCI-H322 metabolized benzo(a)pyrene (BP) at a rate of 160 pmol/106 cells/h for at least 8 h. About 30% of the total metabolites were water-soluble, 30% of which were conjugates with glutathione. The water-soluble fraction also contained BP sulphates but no BP glucuronides.

2. The cytotoxic potency of BP and its metabolites, 3-hydroxybenzo(a)pyrene (3-OH-BP) and (±) anti-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene (7,8-diol-BP), differed by an order of magnitude with the ranking 7,8-diol-BP > BP > 3-OH-BP. The cytotoxicity of BP was not detected at the end of a 24 h treatment period but became increasingly apparent at later times. In contrast, the cytotoxicity of 3-OH-BP was observed immediately after the treatment period and did not increase greatly thereafter. 7,8-Diol-BP caused both ‘immediate’ and ‘late’ effects.

3. The time course and concentration dependence suggested that the cytotoxicity of BP in NCI-H322 cells was not attributable to the formation of 3-OH-BP, but more likely resulted from the formation of other products such as 7,8-diol-BP.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.